Aura Biosciences, Inc. (AURA): Price and Financial Metrics
AURA Price/Volume Stats
| Current price | $7.19 | 52-week high | $13.50 |
| Prev. close | $7.06 | 52-week low | $5.99 |
| Day low | $7.03 | Volume | 162,900 |
| Day high | $7.19 | Avg. volume | 172,500 |
| 50-day MA | $8.08 | Dividend yield | N/A |
| 200-day MA | $9.02 | Market Cap | 355.93M |
AURA Stock Price Chart Interactive Chart >
Aura Biosciences, Inc. (AURA) Company Bio
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform to treat tumors of high unmet need in ocular and urologic oncology. Its AU-011, a VDC candidate, is being developed for the first line treatment of primary choroidal melanoma, a rare disease with no drugs approved. The company also develops AU-011 in additional ocular oncology indications, including choroidal metastases. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Latest AURA News From Around the Web
Below are the latest news stories about AURA BIOSCIENCES INC that investors may wish to consider to help them evaluate AURA as an investment opportunity.
Wall Street Analysts Think Aura Biosciences, Inc. (AURA) Could Surge 174.29%: Read This Before Placing a BetThe average of price targets set by Wall Street analysts indicates a potential upside of 174.3% in Aura Biosciences, Inc. (AURA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal MelanomaBOSTON, December 07, 2023--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the first patient has been dosed in the global Phase 3 CoMpass trial evaluating the safety and efficacy of bel-sar for the first-line treatment of adult patients with early-stage choroidal melanoma. |
Wall Street Analysts Believe Aura Biosciences, Inc. (AURA) Could Rally 200.75%: Here's is How to TradeThe consensus price target hints at a 200.8% upside potential for Aura Biosciences, Inc. (AURA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
David Johnson Bought 232% More Shares In Aura BiosciencesThose following along with Aura Biosciences, Inc. ( NASDAQ:AURA ) will no doubt be intrigued by the recent purchase of... |
Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational HighlightsBOSTON, November 09, 2023--Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the third quarter ended September 30, 2023, and provided clinical development and operational highlights. |
AURA Price Returns
| 1-mo | -15.91% |
| 3-mo | -6.74% |
| 6-mo | -15.41% |
| 1-year | -18.30% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -18.85% |
| 2023 | -15.62% |
| 2022 | -38.16% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...